Good morning, and welcome to the Lexeo Therapeutics webcast presentation. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this call is being recorded. I would like now to turn the conference over to Louis Tamayo, Chief Financial Officer at Lexeo Therapeutics. Louis, please go ahead.
Thank you. Earlier today, we released interim data from the Lexeo HEROIC-PKP2 phase I/II clinical trial of LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy, or ACM. The press release outlining the interim data update is available on our website, as are the slides related to today's call. Before we begin, I would like to remind everyone that today's discussion contains forward-looking statements regarding Lexeo's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our filings with the SEC. With that, I will turn the call over to our CEO, Nolan.
Thanks, Lou. We are pleased to share positive clinical data today demonstrating exciting, clinically meaningful improvements for patients with PKP2 ACM. In the high-dose cohorts, we observed an 80% mean reduction in NSVT burden and a 44% mean reduction in PVC burden at latest assessment. We also observed favorable patient-reported outcomes, encouraging trends in cardiac function, supportive biopsy data, and a well-tolerated safety profile, further strengthening the overall body of evidence for LX2020. We look forward to reviewing these data in greater detail this morning. Importantly, we have also received FDA feedback indicating that the agency is open to guideline-defined NSVT as a surrogate endpoint in a pivotal study for accelerated approval of LX2020. We intend to evaluate NSVT through a responder-based analysis using an established, clinically validated risk threshold, which we will discuss later today.
We currently estimate the pivotal sample size for accelerated approval would include roughly 60 to 80 patients across both treatment and control arms. Given that arrhythmia burden is a key feature of PKP2 ACM, we also expect to incorporate additional measures into the pivotal study, including PVC burden and ICD events, to further characterize clinical benefit. We will continue regulatory discussions with the FDA early next year to finalize the pivotal study design, statistical analysis plan, and confirmatory evidence strategy. Overall, these clinical and regulatory updates strengthen our confidence in the potential of LX2020 to become the first disease-modifying therapy for PKP2 ACM, and we intend to initiate a pivotal study under the accelerated approval pathway in the second half of 2027. Alongside the potential for clinical impact in a patient population with significant unmet need, we believe PKP2 ACM represents a highly attractive commercial opportunity.
Based on the addressable population and the potential value proposition of a one-time disease-modifying therapy, we are confident that LX2020 has the potential to support a multi-billion dollar market opportunity. Importantly, patients are concentrated at a relatively small number of specialized heart failure centers globally, enabling efficient reach, rapid trial enrollment, and a streamlined path to commercial adoption. We also believe Lexeo is well-positioned from a manufacturing perspective, with a scalable production platform designed to support the anticipated commercial demand of a population of this size. Ultimately, commercial success will be driven by our ability to deliver meaningful benefit for patients. The encouraging efficacy and safety data we shared today further strengthen our belief that LX2020 has the potential to become the first disease-modifying therapy for PKP2 ACM, and if successful, addresses a significant unmet need for patients while creating substantial value for shareholders.
With that, I will turn the call over to Nani Bhalla, our Chief Medical Officer, to review the clinical data in greater detail.
Thank you, Nolan. Before we review the data, it is important to understand how we assess treatment response in PKP2 ACM. We evaluate efficacy across three complementary domains: arrhythmic activity, including PVC and NSVT burden; myocardial structure and function, including right ventricular ejection fraction and free wall strain; and patient burden, including patient-reported outcomes. Together, these measures help us assess both clinical benefit and the potential for disease modification. As discussed previously and consistent with KOL feedback, ventricular arrhythmias in ACM exist along a spectrum of increasing clinical risk. PVCs are common and represent early manifestations of electrical instability. NSVT is defined by clinical guidelines as three or more consecutive ventricular beats lasting less than 30 seconds at a rate over 100 beats per minute, which is hemodynamically stable.
Guideline-defined NSVT carries greater prognostic significance than PVCs alone and is associated with a significantly higher risk of future sustained arrhythmias and sudden cardiac death. At the highest risk end of the spectrum are sustained ventricular tachycardia, ICD shocks, and other serious clinical outcomes. NSVT is one of the strongest predictors of future sustained life-threatening ventricular arrhythmias in ACM. That is why it matters as a measure of disease activity and why it has emerged for us as a potential primary endpoint. A common question is how frequently NSVT occurs in patients with PKP2 ACM. As shown on this slide, NSVT is a well-established risk factor used in clinical decisions around ICD implantation, and about 75% of ACM patients receive an ICD during the course of their disease, whether for primary or secondary prevention.
Importantly, because both HEROIC and the SNAPSHOT natural history study enrolled patients with ICDs and a minimum daily threshold of PVCs, these studies selected for a population with substantial underlying arrhythmic risk, including high NSVT incidence. Consistent with that, between 80% and 100% of participants had documented NSVT on baseline Holter monitoring. In addition to arrhythmia burden, we also evaluate systolic function using cardiac MRI. In people with earlier stages of disease, ejection fraction may be stable. RV free wall strain, however, can be a more sensitive marker of muscle function that deteriorates earlier in ACM. Depending on the measurement technique and disease, abnormal wall strain values may be - 10% to - 18%to -20% approximately, whereas normal wall strain values would be - 20% to - 25% to - 30%. Abnormal wall strain is associated with increased risk in ACM of structural progression and future ventricular arrhythmias.
As we will discuss later, rescuing strain may represent improved right ventricular function, particularly if ejection fraction remains largely stable. To briefly cover the study design, HEROIC-PKP2 is a 52-week open-label study with four years of long-term follow-up. The study is fully enrolled with three participants treated at the low dose of 2e13 and seven at the high dose of 6e13 vector genomes per kilogram. As I just mentioned, all participants were required to have an ICD prior to entering the study and to meet a certain level of minimum PVCs, which inherently enriched the study population for those with more severe disease, including NSVT burden at baseline. We feel these inclusion criteria allowed us to enroll participants more likely to need and benefit from gene therapy treatment due to disease burden, and we expect to retain most of these criteria looking ahead in the planned pivotal study.
Baseline characteristics in HEROIC-PKP2 are consistent with the broader PKP2 ACM patient population, with more severe arrhythmia burden in the high-dose cohorts, specifically higher mean PVC and NSVT burden. Nine of 10 participants had a history of sustained VT. As of the October 15th data cutoff, follow-up ranges from 9- 24 months. At the high dose, six of the seven participants have reached at least one year of follow-up. As a reminder, in January of 2026, we evaluated and presented NSVT as total ventricular runs. At the time, that approach allowed us to capture the full spectrum of consecutive ventricular activity.
As we have progressed discussions with regulators and working towards establishing an endpoint with the highest clinical relevance in ACM for the purposes of a pivotal study, we are now focused on NSVT as defined in clinical guidelines, at least three consecutive ventricular beats at a rate greater than 100 beats per minute, terminating spontaneously within 30 seconds. The FDA has also agreed with this definition. As a result, the baseline data were updated using this framework. NSVT event counts decreased because ventricular runs occurring at rates below 100 beats per minute were reclassified as PVCs. Remember, the guideline definition of NSVT notes runs above 100 beats per minute. Importantly, this does not change the underlying ECG recordings or the ventricular activity that occurred. It provides a more clinically meaningful way to classify that activity and evaluate change over time.
Turning now to the clinical data, we have seen encouraging signals of response across arrhythmia burden, cardiac function, and patient-reported outcomes. Patients with a clinically relevant positive response are highlighted in green on the slide. at the latest visit, mean NSVT in the high-dose cohorts improved 80%, and mean PVCs improved 44%. NSVT declined in six of seven participants treated with high dose, with reductions of 75% or more in five participants, well exceeding the impact of current interventions and standard of care. PVCs declined in five of seven participants, and five of seven reported symptom improvement on the Patient Global Impression of Change scale. Five of seven participants also showed improvement in RV free wall strain, with four approaching the lower limit of normal, around -18% to -20%.
Ejection fraction was stable in the majority of participants, although we do see one participant with significant improvement in RVEF at the latest assessment at 18 months. Looking across all parameters together, you can see that every participant in the high-dose cohort showed improvement in at least two parameters of interest, and most showed improvements in three parameters. Overall, these results demonstrated compelling and consistent treatment effect and give us great confidence in the potential of LX2020. Looking at NSVT improvement over time, you can see that mean NSVT reductions in the high-dose cohort continue to deepen with longer follow-up, with mean NSVT falling from approximately 13 episodes per week at baseline to approximately six episodes per week at 12 months and five episodes per week at 18 months. In contrast, participants in the Lexeo-sponsored SNAPSHOT natural history study experienced a 53% mean increase in NSVT over 12 months.
We observed a dose-response treatment effect both in comparison to natural history and the treated patient cohorts at baseline. In the literature and in current clinical practice, NSVT is often assessed in a binary manner. The absence of NSVT reduces future arrhythmic risk, and the presence of NSVT increases risk. Hence, less than one NSVT episode per day is a clinically relevant threshold for management and risk monitoring in ACM. The threshold often used to define the presence of NSVT is more than one episode per day or more than seven episodes per week, and patients above this threshold have a greater risk of future sustained VT events, sometimes irrespective of PVC burden. Importantly, the strength of NSVT as a potential surrogate accelerated approval endpoint lies in its ability to define improvement prospectively against this clinically established threshold, providing a clear and meaningful benchmark for treatment effect.
Looking at the clinical data, most high-dose participants in the HEROIC study exceeded this threshold at baseline, but by 12 months, five of six participants, or 83%, had fewer than one NSVT per day. By comparison, you can see the proportion above this threshold in natural history rose from 27%- 47% over one year, despite the standard of care. As mentioned, because this threshold is established in the literature and clinical practice, it eliminates the need to develop a new definition and supporting evidence of clinically meaningful change in NSVT with regulators, and we believe it provides a clinically relevant framework for a responder-based analysis in the pivotal study. In the planned pivotal study, we intend to measure NSVT burden in this manner rather than looking at a change from baseline. Finally, this slide provides a patient-level view of NSVT burden over time in the high-dose cohort.
What I find particularly encouraging is the consistency of the overall trend. The total NSVT burden across the cohort, shown by the red line, declines meaningfully over time, with reductions becoming more pronounced with longer follow-up. At the latest visit, all seven participants are below the clinically relevant threshold for NSVT burden, experiencing less than seven episodes in seven days, or less than one per day on average. While a few participants demonstrate a transient increase in NSVT immediately following treatment, perhaps due to the excitability in the heart induced by the vector, at later time points, you see the reversal of this trend and significant improvement from baseline. By 12 months, most participants show materially lower NSVT burden relative to baseline, and the overall cohort demonstrates a substantial reduction in aggregate NSVT events.
Importantly, these improvements continue despite the natural history expectation that arrhythmia burden generally remains stable or progresses over time. Taken together, these individual patient trajectories provide evidence that the effect is not being driven by a single outlier, but rather reflects a broader pattern of improvement across the high-dose cohort. Perhaps most importantly, the magnitude of reduction appears to increase with time, which is the pattern we would hope to see from a potentially disease-modifying gene therapy. Looking now at PVCs, mean PVC count in the high-dose cohort decreased 44% at latest assessment, compared with a 14% decrease at 12 months in the SNAPSHOT natural history study.
While there appears to be an increase at 18 months, this change is driven disproportionately by participant five, one of two patients in the sample at this time point, and we believe we would see the positive trend of mean improvement to continue as more patients reach 18 months of follow-up. I would note that PVC burden remains an important measure of disease activity in PKP2-ACM and will be assessed in the future pivotal study. At the same time, PVC measurements are inherently more variable and can be influenced by factors such as physical activity, exercise, stress, and other day-to-day factors. We therefore interpret these results within the context of that known variability. On cardiac MRI, mean RV free wall strain in the high-dose cohorts was abnormal at baseline at -15%, improving to -19% by 12 months.
This improvement moves participants closer to normal values and is consistent with improved myocardial function. Right and left ventricular ejection fraction also remain stable in the majority of participants, potentially indicative of slowed disease progression, so we have evidence of LX2020 positively improving cardiac function as well as arrhythmia burden. I'd like to briefly highlight several exploratory endpoints that provide additional context around the LX2020 clinical profile. Starting with the cardiac biopsy data, these findings provide important mechanistic validation of our gene therapy approach. We observe dose-dependent increases across each step of the expected biological pathway, including vector copy number, exogenous PKP2 messenger RNA expression, and ultimately PKP2 protein production. Taken together, these data provide evidence that LX2020 is successfully reaching target cells, driving gene expression, and increasing levels of PKP2 protein that are deficient in this disease.
Because sample variability can be challenging in ACM, given the presence of fibrotic and fatty replacement tissue in the heart, we do not expect to perform cardiac biopsies in the planned pivotal study, which will reduce the study burden on patients as well. Nevertheless, these data provide encouraging proof of mechanism and biological activity. The ECG findings shown on the bottom of the slide are also exploratory and broadly supportive. We are encouraged that these measures remain generally stable over the follow-up period, potentially indicative of slowed progression when considered alongside the reductions in arrhythmia burden and other evidence of clinical activity observed throughout the study. Lastly, considering major arrhythmic events, many participants in HEROIC have a history of multiple appropriate ICD discharges. However, during the treatment period, only one ICD discharge has occurred in a patient during moderate to strenuous exercise, which is contraindicated in PKP2-ACM.
Finally, in terms of safety, LX2020 continues to be generally well tolerated across all 10 participants dosed. We have not observed any clinically significant complement activation, no participants have discontinued the study, and there are no new treatment-related serious adverse events to report. Ultimately, we believe these interim data demonstrate a compelling and increasingly durable treatment effect. With longer follow-up in the high-dose cohort, we have observed consistent improvements across arrhythmic, functional, and patient-centered measures, further reinforcing our confidence in the potential of LX2020 as a disease-modifying therapy for PKP2-ACM. With that, I'll turn the call back to Nolan.
Thank you, Nani. To summarize, three key themes emerge from today's data. First, LX2020 continues to demonstrate meaningful clinical activity across multiple measures of PKP2-ACM disease burden, including arrhythmic activity, cardiac function, and patient-reported outcomes. Second, with additional follow-up, particularly in the high-dose cohort, we have strengthened our confidence in the magnitude, durability, and safety profile of the treatment effect. Third, regulatory feedback supports a path towards an accelerated approval pivotal study incorporating NSVT as a surrogate endpoint. Together, these clinical and regulatory advancements further strengthen our conviction on the LX2020 program. We look forward to continuing our engagement with regulators, advancing pivotal study planning, and taking the next step toward bringing this therapy to patients. Before we conclude, I'd like to briefly recognize the progress we continue to make across the broader Lexeo portfolio.
In addition to the advancements we've discussed today for LX2020, enrollment in our CLARITY-FA study of LX2006 has continued, and we've now enrolled 26 participants to date. Combined with the financial results reported earlier today, we are pleased with the momentum across the business and remain focused on advancing multiple potentially transformative genetic medicine programs. Finally, I would like to extend my sincere gratitude to the participants, caregivers, investigators, study coordinators, and advocacy organizations whose partnership made the HEROIC-PKP2 study possible. Their commitment and perseverance inspire our work every day, and we remain steadfast in our mission to bring meaningful new treatment options to individuals living with PKP2-ACM.
Thank you. To ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. We ask that you please limit to one question. The first question will come from Paul Matteis with Stifel. Your line is now open.
Hey, good morning. This is Matthew on for Paul. Thank you so much for taking our question, and congrats on the great data. I guess maybe on the NSVTs, have you looked into any patient characteristics that are predictive of greater benefit on NSVTs? For the variability on this endpoint, I am wondering, from one week to the next adjacent week, how much variability are you seeing in this NSVT count? Thank you so much.
Thank you for the question. I think the discussion on the ICDs was meant to give some picture into the profile of patients that would likely have NSVT burden. Maybe I will ask our CMO, Nani, to say a few words about that.
Yeah, thanks, Nolan. Yeah, Matthew, if you think about the patients that we are already enrolling, as I said, we have had patients who all had ICDs, and we had a minimum threshold of PVCs to come into the study. That in itself already brings a particular population into play that has an NSVT burden that is measurable and can be impacted upon by therapy. Regarding the variability, yeah, there is variability that exists, and we did not show these analyses, but we have done some analyses looking at variability and how that changes. What we have seen, really what is impressive, I think, given the context of all the other data we have presented today, is that as you treat these patients, the variability actually starts to narrow dramatically as you see the efficacy kick in.
That's a very strong marker of showing that what you're seeing is true benefit and not just variability, because it's narrowing and you're seeing efficacy. Besides, it's multiple patients, the amount of efficacy we're seeing is well beyond what we would expect from standard of care. All in all, we feel that that's a good indicator that we are well beyond variability when it comes to the variability that you would see normally. Then also, if you think about, no single outlier. If you look at the data we showed on the spaghetti plot, they all have the same trends, they seem to move down together, and they all stabilize. It's again suggesting that there is no individual outlier, that again, not a variability issue that's creating the benefit.
I'd add to that, on an untreated basis, as you saw in our natural history study, you see patients worsening over that 12-month period. I think that's an appropriately representative sample of the type of patients that present with the disease, with ICDs, and so on. There's not great instances of spontaneous improvement in NSVT on an untreated basis. We typically see patients with NSVT disease burden continue to have it throughout the course of the disease, and it worsens in line with what you can observe in our natural history study.
Thank you. That's super encouraging.
Thank you. The next question will come from Roanna Ruiz with Leerink Partners. Your line is open.
Hey. Morning, everyone. Quick one for me. Could you elaborate a bit more on what you would ideally want in a pivotal design in terms of enrollment criteria, a need for confirmatory follow-up or other measures, and a possible control arm? Any additional color you can share about the FDA feedback so far, any outstanding items you still need to discuss, stuff like that would be great.
Yeah. Thanks for the question. I think to start with, what we were trying to indicate in the materials is, we think we're close to the inclusion criteria of what will be a pivotal study here in our phase I/II. Patients with ICDs, with a certain PVC threshold, typically present with NSVT as well. In the materials, we indicated 80%-100% of the patients with that profile from an inclusion criteria perspective would have sustained NSVT burden from a disease course perspective. So, we think we're in the range of an appropriate patient population for this future study as of today. You asked about study design and structure. Maybe I can ask Nani to say a few words about the responder rate approach we're contemplating. I think from a control perspective, that's still an ongoing discussion.
I would say it is feasible to run a controlled study in this disease. Whether it is an open label control similar to what we've done in FA or some other approach, that conversation needs to be finalized. I would say it is feasible to do so in this disease context. Maybe Nani on the responder approach.
Yeah. So, as we mentioned in the webcast, we'll do the responder approach where we're looking at the percent of patients that are above or below the threshold at a particular time point in a treatment versus a control population. That offers a few advantages. One, you've seen the natural history that the burden of NSVT actually increases from 27%- 47% natural history. If you think of the patients that continue to manifest that at a particular time point also remains relatively constant or actually may go up a little bit. Then you contrast that to what we've seen in the treatment group, where there is a dramatic response of patients responding and dropping well below that threshold.
We feel that a responder analysis evaluated by a multi-day multiple Holters or monitoring is going to be the thing that, again, removes variability in addition, but also brings you to a point where you can kind of see the difference between the patients who are responding versus a control population that's likely to remain relatively the same or increase over time.
Yeah. In terms of what's left with respect to the discussion with the FDA, I think there's a discussion on the appropriate statistical plan for this study. There's also a discussion we need to complete on the confirmatory evidence that should support full approval. Ideally, we're running a single study that evaluates the same patients at earlier time points for accelerated approval and the longer time points against clinical endpoints for full approval. That's the strategy that we intend to take here. There's a number of, obviously, important clinical endpoints that could be evaluated in this disease that we will have at secondary endpoints, and that's a discussion we would intend to finalize in the first half.
But I think the FDA indicating their openness to NSVT as an accelerated approval endpoint and some of the other design elements that we began to discuss is an important step forward and something that we will be in a position to finalize in the first half of next year.
That's good. Thanks.
Our next question will come from Kristen Kluska with Cantor Fitzgerald. Your line's open.
Hi, good morning, and huge congrats on this really impressive data. I was hoping you could characterize some of the natural history work for us and how well understood these patients are, assuming not on any treatment. I know there's heterogeneity, of course, on a patient-by-patient difference, but for the most part, do we see that most patients either stay stable or show increased NSVTs over time versus having reductions? Thank you.
Kristen, thank you for the question. Yes. The short answer is yes to your question, but maybe Nani, you want to add a few-
Yeah.
comments to that.
Yeah. So, yeah, the short answer is yes, Kristen. Yes, in the natural history, despite the standard of care, also I would say to you that this is probably one of the first examples where the same patients are being followed over an extended period of time, because a lot of the other natural history studies, patients kind of drop out and it's not always the same patients that end up getting to the end of the study. So, here you have a consistent group that's being followed by multi-day Holters over a couple time points and showing that there is a baseline increase in NSVT.
So, we would expect the burden, at least given this disease profile that we're looking at and the baseline profile that we're looking at, we would expect the NSVT burden to actually increase over time, and then also the number of patients who remain above that threshold to either remain kind of the same or increase over time as well.
Thank you. The next question is going to come from Christopher Raymond with Raymond James. Your line is open.
Hey, thanks and congrats from us on this really outstanding data. Just a maybe a follow-up on the prior regulatory question, in your intent to use a responder analysis in that pivotal study. Was that a suggestion from FDA or was that an idea from you guys? Maybe can you provide any relevant maybe examples we can look at in other rare diseases or gene therapy programs? I'm just trying to get a sense here of whether there's a precedent for this, just kind of noting your comments about how a responder analysis could improve variability, how you think that could affect powering assumptions, trial size, et cetera, going forward. Thanks.
Thanks, Chris, for the question. First, I would say we're probably not at the point today where we can guide to some of the details you just described on powering assumptions and so on. I think we can guide today that we can back into a study that's roughly 60 to 80 patients in totality, and this is in totality across both the treatment arm and a potential either internal control or external control. In terms of responder, I think what's really helpful with the NSVT endpoint is that built into the endpoint, there is this clinically meaningful threshold of improvement that's currently utilized in treatment practice today. If you have greater than one NSVT, it's one of the major criteria for example, having an ICD implanted.
We've taken an existing clinical concept with an existing clinically relevant threshold and converted that into an appropriate endpoint, surrogate endpoint for an accelerated approval study. In that context, a responder rate would obviously make the most sense. Patients that are above that threshold are not responders. Patients that are below that threshold are responders. It makes it a very binary endpoint structure in respect to the study. In terms of responder analyses, I think a number of rare disease studies have utilized them. I can't think offhand of good examples, but I do know that a number of rare disease programs have used responder analyses. I don't know if Nani has-
Yeah. The one I would say is albeit a much larger disease, but still in the rare area is HCM. If you look at the endpoint for pVO2 and gradient reduction, for example, as an endpoint, that was looking at how many patients met that endpoint at the end of the study. So, that's one example that comes to mind right away. Obviously, as I said, a larger rare disease, but one that we can think about right now.
Great. Thank you.
The next question is going to come from Tess Romero with JPMorgan. Your line is open.
Hi, Nolan and team. Thanks so much for taking our question. Just a double-click here on your anticipated pivotal study design. What is the expected duration that you think will enable an accelerated approval? How long do you think you will follow the patients for before conducting a primary analysis based on the data that you have generated, and what have you learned already about what the FDA might want to see? Then second question from us, Nolan, how should we think about, just more broadly, the strategic direction of the portfolio at Lexeo that you are building and where you are really going to prioritize your capital versus where maybe you aren't? Thanks.
The first question was just related to the pivotal study and the length of time. I think our assumption is a 12-month endpoint. We've gotten to above an 80% response rate based on the criteria associated with this endpoint at that time point. So, we think 12 months is an appropriate point in time to focus on from an accelerated approval standpoint. Obviously, we will be following the same patients over longer time points, and that's likely to be the direction of travel from a confirmatory evidence strategy. In terms of capital allocation, maybe I can ask Lou to say a few words about just how we're thinking about capital allocation in the context of this data and the rest of the portfolio.
Yeah. Tess, thank you for the question. I would say, with data like this, we're certainly excited about this program and want to advance it to bring this therapy closer to patients. So, as we think about prioritization and look at the existing cash that we have on hand, which is just shy of $220 million, we're looking at how we can maximize our existing cash and to advance this program forward in the meantime. So, we've guided to early 2027 to give a prioritization update, which was focused on the acquired Mantle assets, but I think with this data, we'll certainly take a look across the portfolio and try to find ways to maximize our existing cash to make progress on this program.
Thank you.
The next question will come from Brian Skorney with Baird. Your line is open.
Hey. Good morning, everyone. Nolan, let me congrats you on the data as well. Just going back to the pivotal design, you said that you think this study generally is consistent with what you think criteria would be for the pivotal. Just on NSVT burden specifically, are you going to put bounds of criteria around baseline NSVT burden? It just seems like particularly with the responder approach, you wouldn't really want to enroll patients who are having fewer than one NSVT per day. Is there an upper limit where you'd be concerned that you wouldn't have good results in terms of getting that response down? In the actual future commercial experience, can you just walk us through how to think about the target population from a commercial perspective?
Would think that severity and risk would predict a desire to take this, but who would you kind of think ideally would be candidates for the gene therapy here? Is it all PKP2 patients? Is it ones with ICDs? Is it ones with a history of sustained VTs? Thanks.
Thanks, Brian, for the question. I think in terms of the target population, we probably wouldn't provide more guidance beyond what we mentioned earlier today with respect to patients with ICDs, with a certain PVC disease burden at baseline. We certainly understand the point of enriching for NSVT and putting some thought to that. But today, as far as we can guide to, I would say it will be patients with ICDs, with a certain PVC threshold, and some additional thinking around how we address the issue that you just highlighted. But I think we're in the range of the population that we would ultimately enroll into the pivotal study today. You can see that in, for example, the natural history study, where over time, you see patients with increasing non-sustained ventricular tachycardia disease burden over the course of that year.
You see the vast majority of the patients in our HEROIC study have NSVT burden at baseline, based on the criteria that we have in the study. More to come on that, but I think we're in the range of the patients that we would ultimately have in the pivotal. With respect to commercial, that's a great question. Obviously, this is a large rare disease, 60,000 patients in total is what's been published. There are patients at different stages of the disease. So, I would say on one end, you have the patients that are a bit later in the disease that are more presenting with symptoms of heart failure, and then you have patients that are earlier in the disease, which may not yet present with the criteria to even have an ICD implanted. So those are the bookends.
Early disease, no ICD yet, they've not reached the level of disease burden to require that, and then late in the disease where patients are presenting with heart failure and progressing towards heart transplants. We would see our commercial opportunity as in the middle of those bookends. This is this population that presents with life-threatening arrhythmias. They have disease burden that's significant enough that they've had an ICD implanted. As mentioned in the materials, those same patients typically present with very meaningful NSVT burden. As we can see, they also, in HEROIC study, that they also present with substantial PVC burden at baseline. So, I think that population in the middle, ICDs implanted, but not yet into the latest stages of the disease that are more the heart failure symptoms, is the population that we'd be focused on, both in the clinical trial and ultimately commercial.
Thank you. The next question will come from Leland Gershell with Oppenheimer. Your line is open.
Oh, great. Thanks for taking our questions. Just wanted to also revisit on the regulatory side. Should we take it, Nolan, to be the case that at this point you expect the guideline-directed NSVT reduction to be sufficient for the accelerated approval? Or do you think that there will be a tie-in to some measure of clinical benefit? Is that kind of where your discussions may be on that? Just wanted to clarify. Thanks.
No, thanks. Yeah, we believe that this NSVT surrogate endpoint would be appropriate for accelerated approval. PVCs will be part of the picture here, probably as a secondary endpoint. They, I think, can corroborate the improvement in NSVT from an arrhythmia burden perspective. That is the direction of travel for accelerated approval. I think for full approval, which would likely be at a later, longer time point, I think we would be looking at some other clinical endpoints. More to come on that, but there are a number of clinical endpoints that are relevant in this disease that you can tie to sustained NSVT disease burden, and that is the other portion of the conversation we will need to finalize with the FDA, such that we can move forward with a single study that addresses both accelerated approval and full approval, potentially with the same patients.
Thanks. Just to follow up, if I may, just on slide 13, the HEROIC data versus the SNAPSHOT natural history study. Just wondering, given the differences in baseline rates of the one NSVT per day threshold, much higher, obviously, in the HEROIC and SNAPSHOT. Just wondering how you may interpret that difference when interpreting those divergences over time. Any sort of matched analyses or other that may distinguish a treatment effect from what could be some regression to the mean? Thanks.
Yeah, I think we will have more out in the public domain in the coming months or quarters on NSVT in terms of our existing natural history and maybe some of the other analyses that have been done at academic centers. So, I probably would not go into a lot of detail except to say, you can see the disease burden in that population. You can see how the disease burden increases. I would not say that the inclusion criteria are exactly identical across the natural history and the treatment study. You saw greater enrichment of NSVT burden in our treatment study. But I think it gives us a good understanding of within the population of ACM for PKP2, what we can expect from NSVT.
What we can expect, as you can see, is that it typically either is flat or worsens over time, and you see sustainment of that disease burden from an NSVT perspective over the course of reasonable periods of time, such as 12 months. I think that's the detail we can offer today, and more to come on NSVT from a natural history perspective as we work to get more of this work out in the public domain.
Thanks very much.
The next question is going to come from Moritz Reiterer with Guggenheim. Your line is open.
Thanks. This is Moritz on for Debjit. Thanks so much for taking our question, and congrats on the great data. Just one more on the assumptions of the pivotal. Can you just share any more details around the assumptions that led you to the estimated 60 to 80 patient size? Thank you so much.
Yeah. This is what we can guide to at this moment. Behind that are a number of power and assumptions that were made, and the design that we are working toward. But the 60 to 80 patients in total is what we can guide to at this point in time.
Okay. Thank you.
Thank you. The last question is going to come from Luca Issi with RBC. Your line is open.
Oh, great. Thanks so much for taking our question. Maybe, Nolan, any additional commentary on safety? If I recall it correctly, you are using materially higher doses for hypertrophic cardiomyopathy versus for dilated cardiomyopathy. Again, appreciate different patient population, different construct, transient, et cetera. But how does the safety of your FA program compare to this program? Are you seeing higher level of ALT elevations and whatnot? I think any call there, much appreciated. Then maybe super quickly on efficacy. It looks like there was only one patient on background antiarrhythmic medication. Was there any antiarrhythmic medications allowed during the study? Again, just trying to understand whether any of the efficacy that we are seeing here is confounded in any capacity by antiarrhythmic medication. So, thanks so much.
Yeah. First on safety, and thank you for the question. I think that's one of the highlights here, is actually the ALT elevations were transient and reported in our last update. They occurred immediately after dosing. They're all managed within the protocol, which means they were all managed in a way that was expected, and we were able to resolve. There were no new treatment-related SAEs that came since that earlier update. The single treatment-related SAE in the study was the patient that had an instance of sustained ventricular tachycardia, which we would look at as the disease itself, and that patient had a history of sustained VT in their treatment history. I think the safety profile here is a real highlight relative to the efficacy, to see no treatment-related SAEs, no classic gene therapy-related SAEs, no complement activation, nothing of that profile here.
We think it's an important highlight, especially as you think about a disease of this size. You're going to try to convince this number of patients to consider a lifetime treatment like gene therapy, you have to have a compelling safety profile associated with that, and I think we're presenting that today alongside meaningful reductions across a number of endpoints that are relevant in the disease. The second question, maybe, Nani you could-
Yeah. On the treatment side, there was one patient who got started. Just on the protocol side, by the way, the antiarrhythmics were, you were not allowed to go on antiarrhythmics unless you were treating some kind of an event. One patient in a high-dose group went on to flecainide three months into treatment, but if you look at the data, that patient actually had a reduction that was well beyond what you would have expected from an antiarrhythmic going on board. This is in comparison to the natural history group, where they were allowed to do whatever they needed to do from the standpoint of antiarrhythmic drugs, et cetera, and then you still see that increase in the number of patients who don't meet thresholds, going from 27%- 47%.
So, at the end of the day, yes, one patient that required treatment early at the three-month time point had reductions, but those reductions well exceeded what would be expected from just going on flecainide at that point.
Yeah, you are looking at six or seven patients with a high dose, nine of 10 total that do not have any background antiarrhythmics. The one that had the antiarrhythmic added was the event that we just described. I think that this is a relatively straightforward and clean data set from a treatment effect perspective, that you are looking at patients here that are improving meaningfully in this disease against a clinically relevant endpoint that the FDA has verified as well, and they are doing so in a sustained and deepening basis over time with a compelling safety profile.
Thank you so much.
I will now turn the call back over to Nolan for closing remarks.
Thank you everyone for joining today. We are excited about the progress in this program, both on the clinical front with respect to this NSVT and PVC improvement that we are seeing across these very important endpoints, also the regulatory clarity that we now have with the path forward into an accelerated approval study next year. As Lou mentioned, we are working to find ways within our existing capital base to move this program forward and to get it into the next trial. We think this represents a meaningful opportunity for patients and the community of PKP2 ACM. I want to thank everyone for joining today and for your interest in this program.
This concludes today's conference call. Thank you for participating, and you may now disconnect.